China, Aug. 10 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A clinical exploratory study on the use of Limertinib sequential combination chemotherapy for advanced NSCLC with EGFR mutations'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600129771
Registration Time: 2026/08/10
Type: Interventional study
Primary Sponsor: Meishan Tumor Hospital
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=321401
Published by HT Digital Content Services with permission from Health Daily Digest....